Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

4.590 -0.080 (-1.71%)
Streaming Delayed Price Updated: 2:55 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62,372
Open 4.670
Bid (Size) 4.580 (1)
Ask (Size) 4.720 (1)
Prev. Close 4.670
Today's Range 4.540 - 4.790
52wk Range 3.810 - 10.64
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
-2.1%
-2.1%
1 Month
-7.3%
-7.3%
3 Month
-6.3%
-6.3%
6 Month
-7.8%
-7.8%
1 Year
-55.6%
-55.6%

More News

Read More
DTIL Revenue Drops 99%
Via The Motley Fool
Topics Intellectual Property
Earnings Scheduled For August 7, 2025
Via Benzinga
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
From Precision BioSciences, Inc.
Via Business Wire
Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’
Via Stocktwits
Discover the top movers in Wednesday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESS Newswire
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Earnings Scheduled For May 15, 2025
Via Benzinga
Uncovering Potential: Precision BioSciences's Earnings Preview
Via Benzinga
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Precision BioSciences, Inc. - Common Stock publicly traded?
Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Precision BioSciences, Inc. - Common Stock trade on?
Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?
The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market
What is the current price of Precision BioSciences, Inc. - Common Stock?
The current price of Precision BioSciences, Inc. - Common Stock is 4.590
When was Precision BioSciences, Inc. - Common Stock last traded?
The last trade of Precision BioSciences, Inc. - Common Stock was at 09/17/25 02:55 PM ET
What is the market capitalization of Precision BioSciences, Inc. - Common Stock?
The market capitalization of Precision BioSciences, Inc. - Common Stock is 522.31M
How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?
Precision BioSciences, Inc. - Common Stock has 522M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.